VBP-245新薬の考察と市場予測（2032年）

当レポートでは、VBP-245新薬の主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）について調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 尋常性疣贅（いぼ）におけるVBP-245の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 治験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（後期の新しい治療法）

第4章 VBP-245市場の評価

• 尋常性疣贅（いぼ）におけるVBP-245の市場の見通し
• 主要7市場の分析
  • 主要7市場の尋常性疣贅（いぼ）向けVBP-245の市場規模
• 市場の分析：国別
  • 米国の尋常性疣贅（いぼ）向けVBP-245の市場規模
  • ドイツの尋常性疣贅（いぼ）向けVBP-245の市場規模
  • 英国の尋常性疣贅（いぼ）向けVBP-245の市場規模

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: VBP-245, Clinical Trial Description, 2023
• Table 2: VBP-245, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: VBP-245 Market Size in the 7MM, in USD million (2019-2032)
• Table 5: VBP-245 Market Size in the US, in USD million (2019-2032)
• Table 6: VBP-245 Market Size in Germany, in USD million (2019-2032)
• Table 7: VBP-245 Market Size in France, in USD million (2019-2032)
• Table 8: VBP-245 Market Size in Italy, in USD million (2019-2032)
• Table 9: VBP-245 Market Size in Spain, in USD million (2019-2032)
• Table 10: VBP-245 Market Size in the UK, in USD million (2019-2032)
• Table 11: VBP-245 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: VBP-245 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: VBP-245 Market Size in the United States, USD million (2019-2032)
• Figure 3: VBP-245 Market Size in Germany, USD million (2019-2032)
• Figure 4: VBP-245 Market Size in France, USD million (2019-2032)
• Figure 5: VBP-245 Market Size in Italy, USD million (2019-2032)
• Figure 6: VBP-245 Market Size in Spain, USD million (2019-2032)
• Figure 7: VBP-245 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: VBP-245 Market Size in Japan, USD million (2019-2032)

"VBP-245 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VBP-245 for Common Warts in the seven major markets. A detailed picture of the VBP-245 for Common Warts in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the VBP-245 for Common Warts. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VBP-245 market forecast, analysis for Common Warts in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Common Warts.

Drug Summary:

VBP-245, topical 2% Povidone-Iodine Gel, is a broad-spectrum anti-microbial that can eradicate microorganisms, including bacteria, viruses, yeasts, molds, fungi, and protozoa. It is well known in the medical community as a pre-operative scrub; however, it is scarcely used outside of this indication despite a strong body of literature supporting its use in various infectious settings.

PVP-I is non-specific in its mechanism of action and therefore lacks the development of resistance that limits the utility of so many conventional antibiotics and antivirals. It inhibits electron transport and cellular respiration, destabilizes membranes, inhibits protein synthesis, and denatures nucleic acid.

PVP-I's lack of resistance lent itself very well to verruca vulgaris as well, and it was then selected as the follow-up indication. The treatment course of these typically lasts up to a year, and resistance to the antifungals remains a limiting factor of treatment. A topical solution was developed that could be easily applied to and under the nail apparatus.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VBP-245 description, mechanism of action, dosage and administration, research and development activities in Common Warts.
• Elaborated details on VBP-245 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VBP-245 research and development activity in Common Warts in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VBP-245.
• The report contains forecasted sales of VBP-245 for Common Warts till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Common Warts.
• The report also features the SWOT analysis with analyst views for VBP-245 in Common Warts.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VBP-245 Analytical Perspective by DelveInsight

• In-depth VBP-245 Market Assessment

This report provides a detailed market assessment of VBP-245 in Common Warts in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• VBP-245 Clinical Assessment

The report provides the clinical trials information of VBP-245 in Common Warts covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Common Warts is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VBP-245 dominance.
• Other emerging products for Common Warts are expected to give tough market competition to VBP-245 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VBP-245 in Common Warts.
• Our in-depth analysis of the forecasted sales data from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VBP-245 in Common Warts.  

Key Questions

• What is the product type, route of administration and mechanism of action of VBP-245?
• What is the clinical trial status of the study related to VBP-245 in Common Warts and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VBP-245 development?
• What are the key designations that have been granted to VBP-245 for Common Warts?
• What is the forecasted market scenario of VBP-245 for Common Warts?
• What are the forecasted sales of VBP-245 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Common Warts and how are they giving competition to VBP-245 for Common Warts?
• Which are the late-stage emerging therapies under development for the treatment of Common Warts?

Table of Contents

1. Report Introduction

2. VBP-245 Overview in Common Warts

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. VBP-245 Market Assessment

• 4.1. Market Outlook of VBP-245 in Common Warts
• 4.2. 7MM Analysis
  • 4.2.1. Market size of VBP-245 in the 7MM for Common Warts
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market size of VBP-245 in the United States for Common Warts
  • 4.3.2. Market size of VBP-245 in Germany for Common Warts
  • 4.3.3. Market size of VBP-245 in France for Common Warts
  • 4.3.4. Market size of VBP-245 in Italy for Common Warts
  • 4.3.5. Market size of VBP-245 in Spain for Common Warts
  • 4.3.6. Market size of VBP-245 in the United Kingdom for Common Warts
  • 4.3.7. Market size of VBP-245 in Japan for Common Warts

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options